<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jensen MA</submitter><funding>NIDDK NIH HHS</funding><funding>NCRR NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>NIAMS NIH HHS</funding><pagination>596-601</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3910490</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>72(4)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>Hyperactivity of the type I interferon (IFN) pathway is involved in the pathogenesis of systemic lupus erythematosus (SLE). Immunoglobulin like transcript (ILT3) is an immunohibitory transmembrane molecule which is induced by type I IFNs. ILT3 is expressed by plasmacytoid dendritic cells (PDCs), monocytoid dendritic cells (MDCs), and monocytes/macrophages. Given the pathogenic role of IFN in SLE, we hypothesised that the IFN-induced immunosuppressive ILT3 receptor may be dysfunctional in human SLE.&lt;h4>Methods&lt;/h4>132 European-derived and 79 Hispanic-American SLE patients were genotyped for two coding-change single nucleotide polymorphisms (SNPs) predicted to interfere with protein folding in ILT3 (rs11540761 and rs1048801). 116 control DNA samples and sera from healthy co</pubmed_abstract><journal>Annals of the rheumatic diseases</journal><pubmed_title>Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients.</pubmed_title><pmcid>PMC3910490</pmcid><funding_grant_id>UL1 RR024999</funding_grant_id><funding_grant_id>AI071651</funding_grant_id><funding_grant_id>P30 DK042086</funding_grant_id><funding_grant_id>K08 AI083790</funding_grant_id><funding_grant_id>P30 DK42086</funding_grant_id><funding_grant_id>L30 AI071651</funding_grant_id><funding_grant_id>R01 AR060861</funding_grant_id><pubmed_authors>Jensen MA</pubmed_authors><pubmed_authors>Kumar AA</pubmed_authors><pubmed_authors>Kumabe M</pubmed_authors><pubmed_authors>Patterson KC</pubmed_authors><pubmed_authors>Franek BS</pubmed_authors><pubmed_authors>Niewold TB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients.</name><description>&lt;h4>Objective&lt;/h4>Hyperactivity of the type I interferon (IFN) pathway is involved in the pathogenesis of systemic lupus erythematosus (SLE). Immunoglobulin like transcript (ILT3) is an immunohibitory transmembrane molecule which is induced by type I IFNs. ILT3 is expressed by plasmacytoid dendritic cells (PDCs), monocytoid dendritic cells (MDCs), and monocytes/macrophages. Given the pathogenic role of IFN in SLE, we hypothesised that the IFN-induced immunosuppressive ILT3 receptor may be dysfunctional in human SLE.&lt;h4>Methods&lt;/h4>132 European-derived and 79 Hispanic-American SLE patients were genotyped for two coding-change single nucleotide polymorphisms (SNPs) predicted to interfere with protein folding in ILT3 (rs11540761 and rs1048801). 116 control DNA samples and sera from healthy co</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013 Apr</publication><modification>2026-05-03T02:14:12.262Z</modification><creation>2019-03-27T01:21:05Z</creation></dates><accession>S-EPMC3910490</accession><cross_references><pubmed>22904259</pubmed><doi>10.1136/annrheumdis-2012-202024</doi></cross_references></HashMap>